Compare ARDX & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | NEO |
|---|---|---|
| Founded | 2007 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2014 | 1999 |
| Metric | ARDX | NEO |
|---|---|---|
| Price | $6.23 | $11.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 10 |
| Target Price | $10.65 | ★ $12.56 |
| AVG Volume (30 Days) | ★ 2.7M | 1.8M |
| Earning Date | 10-30-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $398,234,000.00 | ★ $709,162,000.00 |
| Revenue This Year | $22.71 | $10.90 |
| Revenue Next Year | $27.81 | $9.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 58.12 | 10.10 |
| 52 Week Low | $3.21 | $4.72 |
| 52 Week High | $6.78 | $19.12 |
| Indicator | ARDX | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 62.17 | 60.77 |
| Support Level | $5.77 | $11.59 |
| Resistance Level | $6.20 | $12.26 |
| Average True Range (ATR) | 0.27 | 0.42 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 91.30 | 49.80 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.